Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients
Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. It has been suggested that not only the virus but also the interaction between the virus and the host immune system is important in determining the course of the infection and the response to interferon (IFN)-based therapy. Wh...
Gespeichert in:
| Veröffentlicht in: | Archives of virology 2015-09, Vol.160 (9), p.2181-2195 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2195 |
|---|---|
| container_issue | 9 |
| container_start_page | 2181 |
| container_title | Archives of virology |
| container_volume | 160 |
| creator | Sadik, Nermin Abdel Hamid Shaker, Olfat Gamil Ghanem, Hassan Zaki Hassan, Heba Akram Abdel-Hamid, Abdel-Hamid Zaki |
| description | Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. It has been suggested that not only the virus but also the interaction between the virus and the host immune system is important in determining the course of the infection and the response to interferon (IFN)-based therapy. While the adaptive immune system plays a critical role in HCV infection, the innate immune system has only been recognized recently. Toll-like receptors (TLRs) form the cornerstone of the innate immune response. Interleukin-10 (IL-10) is one of the upstream regulators of TLR4. A possible interplay between TLR4 and IL-10 has been suggested. The present study aimed to investigate the role of single-nucleotide polymorphisms (SNPs) in TLR4 and IL-10-1082 and the expression levels of these proteins in predicting the response to treatment in chronic HCV patients. A total of 83 chronic HCV-infected Egyptian patients treated with peg-IFN-α2b–ribavirin combination therapy and 40 healthy subjects were included in this study. SNPs in the TLR4 rs2149356 and IL-10-1082 genes and their serum levels were assessed. Within the responders group, T/T and A/A genotypes were the significantly most frequent genotypes of TLR4 and IL-10-1082, respectively. Moreover, a higher frequency of T/T and A/A was found to be associated with lower serum TLR4 and IL-10 levels in our responder patients. In addition, subjects with the T/T genotype in the healthy control group had a lower serum TLR4 level than those with other genotypes. We conclude that the SNPs TLR4 rs2149356-T/T and IL-10-1082-A/A may be important predictors for HCV therapy. |
| doi_str_mv | 10.1007/s00705-015-2493-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1712775635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1708896790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-ee714e5a9acb0b7e4bfe23179ca3a2b74c53aa95c7cb3ec1882a363b97fdd0863</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhSMEotPCA7ABS2zYGOw4ju0lGpUfqRKLtmvLcW5m3CZ2sJ3FvEqfto5SEGKB2PjvfOdYV6eq3lDykRIiPqWyEI4J5bhuFMPkWbWjDauxFEo-r3aEkQbLlsiz6jylO0LKA-Mvq7O6JYpT2e6qh2vnDyNgv9gRQnY9oDmMpynE-ejShMKAbsI44tHdA4pgYc4hogYZ3yPnM8QRlnvnMSXlWoA0B58A5bCpA8TgcWcS9CgfIZr5tHKXh9OcnfHIHovuLDrCbLLLLqE9Wk_gc3pVvRjMmOD1035R3X65vNl_w1c_vn7ff77CtlEqYwBBG-BGGduRTkDTDVAzKpQ1zNSdaCxnxihuhe0YWCplbVjLOiWGvieyZRfVhy13juHnAinrySUL42g8hCVpKmgtBG8Z_w-USKlaoUhB3_-F3oUl-jLISgklpOIrRTfKxpBShEHP0U0mnjQleu1Ybx3r0rFeO9ar5-1T8tJN0P92_Cq1APUGpCL5A8Q_vv5H6rvNNJigzSG6pG-va0JbQsr4vJHsEceevRo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1707978950</pqid></control><display><type>article</type><title>Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Sadik, Nermin Abdel Hamid ; Shaker, Olfat Gamil ; Ghanem, Hassan Zaki ; Hassan, Heba Akram ; Abdel-Hamid, Abdel-Hamid Zaki</creator><creatorcontrib>Sadik, Nermin Abdel Hamid ; Shaker, Olfat Gamil ; Ghanem, Hassan Zaki ; Hassan, Heba Akram ; Abdel-Hamid, Abdel-Hamid Zaki</creatorcontrib><description>Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. It has been suggested that not only the virus but also the interaction between the virus and the host immune system is important in determining the course of the infection and the response to interferon (IFN)-based therapy. While the adaptive immune system plays a critical role in HCV infection, the innate immune system has only been recognized recently. Toll-like receptors (TLRs) form the cornerstone of the innate immune response. Interleukin-10 (IL-10) is one of the upstream regulators of TLR4. A possible interplay between TLR4 and IL-10 has been suggested. The present study aimed to investigate the role of single-nucleotide polymorphisms (SNPs) in TLR4 and IL-10-1082 and the expression levels of these proteins in predicting the response to treatment in chronic HCV patients. A total of 83 chronic HCV-infected Egyptian patients treated with peg-IFN-α2b–ribavirin combination therapy and 40 healthy subjects were included in this study. SNPs in the TLR4 rs2149356 and IL-10-1082 genes and their serum levels were assessed. Within the responders group, T/T and A/A genotypes were the significantly most frequent genotypes of TLR4 and IL-10-1082, respectively. Moreover, a higher frequency of T/T and A/A was found to be associated with lower serum TLR4 and IL-10 levels in our responder patients. In addition, subjects with the T/T genotype in the healthy control group had a lower serum TLR4 level than those with other genotypes. We conclude that the SNPs TLR4 rs2149356-T/T and IL-10-1082-A/A may be important predictors for HCV therapy.</description><identifier>ISSN: 0304-8608</identifier><identifier>EISSN: 1432-8798</identifier><identifier>DOI: 10.1007/s00705-015-2493-0</identifier><identifier>PMID: 26095186</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>adaptive immunity ; Adult ; Antiviral Agents - therapeutic use ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; blood serum ; chronic hepatitis C ; Cytokines ; Drug Therapy, Combination - methods ; Egypt ; Female ; Gene Frequency ; genes ; Genotype ; Growth factors ; Health surveys ; Hepatitis B ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Humans ; Immune system ; Infections ; Infectious Diseases ; innate immunity ; Interferon ; Interferon-alpha - therapeutic use ; interferons ; Interferons - therapeutic use ; interleukin-10 ; Interleukin-10 - genetics ; Kinases ; Male ; Medical Microbiology ; Middle Aged ; Original Article ; patients ; Polyethylene Glycols - therapeutic use ; Polymorphism ; Polymorphism, Single Nucleotide ; prediction ; Prospective Studies ; Recombinant Proteins - therapeutic use ; Ribavirin - therapeutic use ; single nucleotide polymorphism ; therapeutics ; Toll-like receptor 4 ; Toll-Like Receptor 4 - genetics ; Treatment Outcome ; Tumor necrosis factor-TNF ; Virology ; Viruses ; Young Adult</subject><ispartof>Archives of virology, 2015-09, Vol.160 (9), p.2181-2195</ispartof><rights>Springer-Verlag Wien 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-ee714e5a9acb0b7e4bfe23179ca3a2b74c53aa95c7cb3ec1882a363b97fdd0863</citedby><cites>FETCH-LOGICAL-c499t-ee714e5a9acb0b7e4bfe23179ca3a2b74c53aa95c7cb3ec1882a363b97fdd0863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00705-015-2493-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00705-015-2493-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26095186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sadik, Nermin Abdel Hamid</creatorcontrib><creatorcontrib>Shaker, Olfat Gamil</creatorcontrib><creatorcontrib>Ghanem, Hassan Zaki</creatorcontrib><creatorcontrib>Hassan, Heba Akram</creatorcontrib><creatorcontrib>Abdel-Hamid, Abdel-Hamid Zaki</creatorcontrib><title>Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients</title><title>Archives of virology</title><addtitle>Arch Virol</addtitle><addtitle>Arch Virol</addtitle><description>Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. It has been suggested that not only the virus but also the interaction between the virus and the host immune system is important in determining the course of the infection and the response to interferon (IFN)-based therapy. While the adaptive immune system plays a critical role in HCV infection, the innate immune system has only been recognized recently. Toll-like receptors (TLRs) form the cornerstone of the innate immune response. Interleukin-10 (IL-10) is one of the upstream regulators of TLR4. A possible interplay between TLR4 and IL-10 has been suggested. The present study aimed to investigate the role of single-nucleotide polymorphisms (SNPs) in TLR4 and IL-10-1082 and the expression levels of these proteins in predicting the response to treatment in chronic HCV patients. A total of 83 chronic HCV-infected Egyptian patients treated with peg-IFN-α2b–ribavirin combination therapy and 40 healthy subjects were included in this study. SNPs in the TLR4 rs2149356 and IL-10-1082 genes and their serum levels were assessed. Within the responders group, T/T and A/A genotypes were the significantly most frequent genotypes of TLR4 and IL-10-1082, respectively. Moreover, a higher frequency of T/T and A/A was found to be associated with lower serum TLR4 and IL-10 levels in our responder patients. In addition, subjects with the T/T genotype in the healthy control group had a lower serum TLR4 level than those with other genotypes. We conclude that the SNPs TLR4 rs2149356-T/T and IL-10-1082-A/A may be important predictors for HCV therapy.</description><subject>adaptive immunity</subject><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>blood serum</subject><subject>chronic hepatitis C</subject><subject>Cytokines</subject><subject>Drug Therapy, Combination - methods</subject><subject>Egypt</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>genes</subject><subject>Genotype</subject><subject>Growth factors</subject><subject>Health surveys</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Immune system</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>innate immunity</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>interferons</subject><subject>Interferons - therapeutic use</subject><subject>interleukin-10</subject><subject>Interleukin-10 - genetics</subject><subject>Kinases</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>patients</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide</subject><subject>prediction</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Ribavirin - therapeutic use</subject><subject>single nucleotide polymorphism</subject><subject>therapeutics</subject><subject>Toll-like receptor 4</subject><subject>Toll-Like Receptor 4 - genetics</subject><subject>Treatment Outcome</subject><subject>Tumor necrosis factor-TNF</subject><subject>Virology</subject><subject>Viruses</subject><subject>Young Adult</subject><issn>0304-8608</issn><issn>1432-8798</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkc1u1DAUhSMEotPCA7ABS2zYGOw4ju0lGpUfqRKLtmvLcW5m3CZ2sJ3FvEqfto5SEGKB2PjvfOdYV6eq3lDykRIiPqWyEI4J5bhuFMPkWbWjDauxFEo-r3aEkQbLlsiz6jylO0LKA-Mvq7O6JYpT2e6qh2vnDyNgv9gRQnY9oDmMpynE-ejShMKAbsI44tHdA4pgYc4hogYZ3yPnM8QRlnvnMSXlWoA0B58A5bCpA8TgcWcS9CgfIZr5tHKXh9OcnfHIHovuLDrCbLLLLqE9Wk_gc3pVvRjMmOD1035R3X65vNl_w1c_vn7ff77CtlEqYwBBG-BGGduRTkDTDVAzKpQ1zNSdaCxnxihuhe0YWCplbVjLOiWGvieyZRfVhy13juHnAinrySUL42g8hCVpKmgtBG8Z_w-USKlaoUhB3_-F3oUl-jLISgklpOIrRTfKxpBShEHP0U0mnjQleu1Ybx3r0rFeO9ar5-1T8tJN0P92_Cq1APUGpCL5A8Q_vv5H6rvNNJigzSG6pG-va0JbQsr4vJHsEceevRo</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Sadik, Nermin Abdel Hamid</creator><creator>Shaker, Olfat Gamil</creator><creator>Ghanem, Hassan Zaki</creator><creator>Hassan, Heba Akram</creator><creator>Abdel-Hamid, Abdel-Hamid Zaki</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients</title><author>Sadik, Nermin Abdel Hamid ; Shaker, Olfat Gamil ; Ghanem, Hassan Zaki ; Hassan, Heba Akram ; Abdel-Hamid, Abdel-Hamid Zaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-ee714e5a9acb0b7e4bfe23179ca3a2b74c53aa95c7cb3ec1882a363b97fdd0863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>adaptive immunity</topic><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>blood serum</topic><topic>chronic hepatitis C</topic><topic>Cytokines</topic><topic>Drug Therapy, Combination - methods</topic><topic>Egypt</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>genes</topic><topic>Genotype</topic><topic>Growth factors</topic><topic>Health surveys</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Immune system</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>innate immunity</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>interferons</topic><topic>Interferons - therapeutic use</topic><topic>interleukin-10</topic><topic>Interleukin-10 - genetics</topic><topic>Kinases</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>patients</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide</topic><topic>prediction</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Ribavirin - therapeutic use</topic><topic>single nucleotide polymorphism</topic><topic>therapeutics</topic><topic>Toll-like receptor 4</topic><topic>Toll-Like Receptor 4 - genetics</topic><topic>Treatment Outcome</topic><topic>Tumor necrosis factor-TNF</topic><topic>Virology</topic><topic>Viruses</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sadik, Nermin Abdel Hamid</creatorcontrib><creatorcontrib>Shaker, Olfat Gamil</creatorcontrib><creatorcontrib>Ghanem, Hassan Zaki</creatorcontrib><creatorcontrib>Hassan, Heba Akram</creatorcontrib><creatorcontrib>Abdel-Hamid, Abdel-Hamid Zaki</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sadik, Nermin Abdel Hamid</au><au>Shaker, Olfat Gamil</au><au>Ghanem, Hassan Zaki</au><au>Hassan, Heba Akram</au><au>Abdel-Hamid, Abdel-Hamid Zaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients</atitle><jtitle>Archives of virology</jtitle><stitle>Arch Virol</stitle><addtitle>Arch Virol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>160</volume><issue>9</issue><spage>2181</spage><epage>2195</epage><pages>2181-2195</pages><issn>0304-8608</issn><eissn>1432-8798</eissn><abstract>Egypt has the highest prevalence of hepatitis C virus (HCV) in the world. It has been suggested that not only the virus but also the interaction between the virus and the host immune system is important in determining the course of the infection and the response to interferon (IFN)-based therapy. While the adaptive immune system plays a critical role in HCV infection, the innate immune system has only been recognized recently. Toll-like receptors (TLRs) form the cornerstone of the innate immune response. Interleukin-10 (IL-10) is one of the upstream regulators of TLR4. A possible interplay between TLR4 and IL-10 has been suggested. The present study aimed to investigate the role of single-nucleotide polymorphisms (SNPs) in TLR4 and IL-10-1082 and the expression levels of these proteins in predicting the response to treatment in chronic HCV patients. A total of 83 chronic HCV-infected Egyptian patients treated with peg-IFN-α2b–ribavirin combination therapy and 40 healthy subjects were included in this study. SNPs in the TLR4 rs2149356 and IL-10-1082 genes and their serum levels were assessed. Within the responders group, T/T and A/A genotypes were the significantly most frequent genotypes of TLR4 and IL-10-1082, respectively. Moreover, a higher frequency of T/T and A/A was found to be associated with lower serum TLR4 and IL-10 levels in our responder patients. In addition, subjects with the T/T genotype in the healthy control group had a lower serum TLR4 level than those with other genotypes. We conclude that the SNPs TLR4 rs2149356-T/T and IL-10-1082-A/A may be important predictors for HCV therapy.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>26095186</pmid><doi>10.1007/s00705-015-2493-0</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-8608 |
| ispartof | Archives of virology, 2015-09, Vol.160 (9), p.2181-2195 |
| issn | 0304-8608 1432-8798 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1712775635 |
| source | MEDLINE; SpringerLink Journals |
| subjects | adaptive immunity Adult Antiviral Agents - therapeutic use Biochemistry Biomedical and Life Sciences Biomedicine blood serum chronic hepatitis C Cytokines Drug Therapy, Combination - methods Egypt Female Gene Frequency genes Genotype Growth factors Health surveys Hepatitis B Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Humans Immune system Infections Infectious Diseases innate immunity Interferon Interferon-alpha - therapeutic use interferons Interferons - therapeutic use interleukin-10 Interleukin-10 - genetics Kinases Male Medical Microbiology Middle Aged Original Article patients Polyethylene Glycols - therapeutic use Polymorphism Polymorphism, Single Nucleotide prediction Prospective Studies Recombinant Proteins - therapeutic use Ribavirin - therapeutic use single nucleotide polymorphism therapeutics Toll-like receptor 4 Toll-Like Receptor 4 - genetics Treatment Outcome Tumor necrosis factor-TNF Virology Viruses Young Adult |
| title | Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T10%3A18%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single-nucleotide%20polymorphism%20of%20Toll-like%20receptor%204%20and%20interleukin-10%20in%20response%20to%20interferon-based%20therapy%20in%20Egyptian%20chronic%20hepatitis%20C%20patients&rft.jtitle=Archives%20of%20virology&rft.au=Sadik,%20Nermin%20Abdel%20Hamid&rft.date=2015-09-01&rft.volume=160&rft.issue=9&rft.spage=2181&rft.epage=2195&rft.pages=2181-2195&rft.issn=0304-8608&rft.eissn=1432-8798&rft_id=info:doi/10.1007/s00705-015-2493-0&rft_dat=%3Cproquest_cross%3E1708896790%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1707978950&rft_id=info:pmid/26095186&rfr_iscdi=true |